These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 16356307)
1. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Noronha V; Burtness B; Murren J; Duffy TP Clin Colorectal Cancer; 2005 Nov; 5(4):283-6. PubMed ID: 16356307 [TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. Cobo F; De Celis G; Pereira A; Latorre X; Pujadas J; Albiol S Anticancer Drugs; 2007 Sep; 18(8):973-6. PubMed ID: 17667605 [TBL] [Abstract][Full Text] [Related]
3. Leucovorin-induced hypersensitivity reaction. Damaske A; Ma N; Williams R J Oncol Pharm Pract; 2012 Mar; 18(1):136-9. PubMed ID: 21248170 [TBL] [Abstract][Full Text] [Related]
4. Acute immune hematological complication of oxaliplatin. A series of 3 cases. Garciaz S; Oziel-Taieb S; Dermeche S; Ries P; Vessaud J; Raoul JL Tumori; 2014; 100(1):e17-9. PubMed ID: 24675502 [TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity reactions to oxaliplatin in two asian patients. Ng CV Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290 [TBL] [Abstract][Full Text] [Related]
6. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer. Nozawa H; Muto Y; Yamada Y Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472 [TBL] [Abstract][Full Text] [Related]
7. [Two cases of advanced colorectal cancer which demonstrated the reversibility of oxaliplatin-mediated increase in splenic volume]. Motoori S; Kawase T; Nishimura H; Hosokawa Y; Konno T; Hanai C; Kitagawa N; Saisho H; Furuse J Gan To Kagaku Ryoho; 2011 Apr; 38(4):677-80. PubMed ID: 21499004 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-induced immune mediated thrombocytopenia. Beg MS; Komrokji RS; Ahmed K; Safa MM Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841 [TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066 [TBL] [Abstract][Full Text] [Related]
10. Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review. Lai JI; Wang WS Pharm World Sci; 2009 Oct; 31(5):538-541. PubMed ID: 19588266 [TBL] [Abstract][Full Text] [Related]
11. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215 [No Abstract] [Full Text] [Related]
12. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer. Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916 [TBL] [Abstract][Full Text] [Related]
14. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Curtis SA; Curtis BR; Lee AI; Hendrickson JE; Lacy J; Podoltsev NA Hematology; 2018 Aug; 23(7):429-432. PubMed ID: 29281948 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Horimatsu T; Miyamoto S; Morita S; Mashimo Y; Ezoe Y; Muto M; Chiba T Cancer Chemother Pharmacol; 2011 Jul; 68(1):263-6. PubMed ID: 21499694 [TBL] [Abstract][Full Text] [Related]